Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma
Mandate

Vinge advises Medivir on its divestment of BioPhausia to Karo Pharma

November 03, 2016

Medivir AB (publ) (Nasdaq Stockholm) has entered into an agreement with Karo Pharma AB (publ) (Nasdaq Stockholm) regarding the sale of Medivir’s subsidiary BioPhausia (Nordic Brands) to Karo Pharma. The purchase price is SEK 908 million and the transaction is expected to close by mid-December 2016.
 
Vinge advises Medivir. The Vinge team includes Erik Sjöman, Anna Edström, Mattias Sköld, Dain Hård Nevonen, Rikard Lindahl and Ludvig Frithiof, and Fredrik Dahl and Sara Strandberg (employment law).

Related

Vinge advises SBB in connection with its acquisition of shares in PPI against payment through a share issue in-kind

 Vinge has advised SBB in connection with the agreement entered into with TRG, a Norwegian group of companies controlled by Kjell Inge Røkke and the principal owner of Aker ASA. Under the agreement, SBB has undertaken to carry out a share issue in-kind to TRG or, as applicable, Aker Property Group.
May 16, 2025

Vinge has advised Stendörren Fastigheter in connection with a directed share issue of approximately SEK 300 million

 Vinge has advised the property company Stendörren Fastigheter AB (publ) in connection with a directed share issue through which the company raises proceeds of approximately SEK 300 million before transaction costs.
May 14, 2025

Vinge has advised EQT AB in connection with its bond issue in the aggregate principal amount of USD 500,000,000

 EQT AB (publ) has issued senior bonds in the aggregate principal amount of USD 500,000,000 with an interest rate of 5.850%, due 2035, at a price equal to 99.783% of the aggregate principal amount thereof.
May 13, 2025